Repair effects of leramistat in participants with rheumatoid arthritis

A randomised, double-blind, placebo-controlled trial of the effects of leramistat (MBS2320) on muscle in participants with rheumatoid arthritis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16456769

Enrollment

Registered

2026-05-01

Start date

2026-04-20

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis Musculoskeletal Diseases

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Exclusion criteria

Exclusion criteria: The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Design outcomes

Primary

Measure	Time frame
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date	—

Secondary

Measure	Time frame
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date	—

Countries

England, United Kingdom

Contacts

Public ContactJohn;Asma Isaacs;Abdul Malek

;

Nuth.ist3@nhs.net;Nuth.ist3@nhs.net44 (0)191 213 7118;-

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 23, 2026